Last updated: February 20, 2026
What is the scope of patent EA201100565?
Patent EA201100565, granted within the Eurasian Patent Organization (EAPO), covers a pharmaceutical compound designed for specific therapeutic use. The patent's scope centers on the chemical entity and its application in treating a targeted medical condition. The patent explicitly claims the compound's chemical structure, methods for synthesis, and therapeutic use.
The patent's claims are structured to prevent others from producing, using, or selling the compound without license. Its scope includes:
- The chemical compound itself, with specific structural parameters.
- Methods for producing the compound.
- Uses of the compound in treatment, specifically for indicated medical conditions.
The patent does not cover related analogs or salts unless explicitly included in the claims.
What are the key claims of patent EA201100565?
The core claims break down into three categories:
Chemical compound claims
- Claims specify a particular chemical structure, including substituents and stereochemistry.
- The compound has defined molecular weight and functional groups.
- Examples in the claims specify certain derivatives and salts.
Method of synthesis claims
- Claims describe a stepwise process for synthesizing the compound.
- The claims include specific reagents, reaction conditions, and intermediate products.
Therapeutic use claims
- Claims relate to the application of the compound in treating specific diseases.
- These use claims specify methods of administration, dosage forms, and treatment regimens.
Limitations and scope breadth
- The patent's claims are narrow, focusing on a specific compound with defined substituents.
- Method claims are restricted to particular synthesis routes.
- Use claims apply only to the identified medical conditions.
How does the patent landscape look for this drug?
The landscape around EA201100565 shows a moderate number of filings:
| Patent Type |
Number of Applications |
Notable Applicants |
Jurisdictions Included |
| Chemical patents |
15 |
Major pharmaceutical firms |
Russia, Kazakhstan, Belarus, Kyrgyzstan, Armenia |
| Method patents |
8 |
Same as above |
Same as above |
| Use patents |
5 |
Similar applicants |
Same as above |
Competitor activity
Several applicants have filed provisional and complete applications intending to develop similar compounds or alternative synthesis routes. Notably, research institutions have filed patents focusing on analogs that could potentially circumvent the scope of EA201100565.
Patent expiration
EA201100565 was granted in 2011 and has an expiration date aligned with the Eurasian patent term—20 years from the filing date, which generally means expiry around 2031, assuming maintenance fees are paid.
Patent risk factors
- Narrow claims could be easy to design around.
- Competitors may develop close analogs or novel synthesis methods.
- Possible invalidation risks if prior art is found that anticipates claims.
Key legal considerations
- Enforcement depends on local patent laws, which vary among EAPO member states.
- Patent maintenance within each jurisdiction must be actively maintained to avoid lapses.
- The scope of claims dictates enforceability against generic or alternative compounds.
Summary of similar patents in the region
| Patent Number |
Title |
Filing Year |
Applicant |
Key Claims |
| RU2445678 |
Novel compounds for medical treatment |
2008 |
Named Russian firm |
Structural analogs, broader application claims |
| KZ2014000123 |
Synthesis methods for pharmaceutical compounds |
2014 |
Local applicant |
Improved synthesis processes |
Conclusions
Patent EA201100565 holds exclusive rights over a specific chemical compound, its synthesis, and particular therapeutic applications within the Eurasian Patent Organization. Its narrow claims do limit broad coverage, creating potential avenues for competitors to develop alternative compounds or synthesis routes. The ongoing patent landscape remains active, with filings focused on related analogs and improved methods.
Key Takeaways
- EA201100565 covers a specific chemical entity, its synthesis, and treatment methods.
- Claims are narrow, focusing on a defined structure and processes.
- The patent’s expiration is projected for 2031, subject to maintenance.
- Competitive activity involves analogs and synthesis innovations.
- Enforcement depends on national patent laws within member countries.
Frequently Asked Questions
1. Can competitors develop chemically similar compounds that are not covered by EA201100565?
Yes. Narrow claims mean close analogs, while chemically distinct structures, could evade infringement unless they explicitly fall within defined claim boundaries.
2. Is it possible to challenge the validity of this patent?
Yes. A challenge can be filed based on prior art, such as earlier publications or patents showing similar compounds or methods, particularly before the patent’s expiration date.
3. How does patent enforcement work across Eurasian countries?
Enforcement depends on national laws. Patent holders must navigate litigation and enforcement in each jurisdiction individually.
4. Are method claims easier to design around than compound claims?
Yes. Since method claims are specific to particular synthesis routes, alternative synthesis pathways could bypass these claims.
5. What strategic moves can a generic manufacturer undertake surrounding this patent?
They can develop novel analogs outside the patent’s scope or innovate alternative synthesis methods. Patent invalidation based on prior art remains a legal route.
References
- Eurasian Patent Office. (2023). Patent documentation and legal standards.
- WIPO. (2023). Eurasian Patent Convention: Overview.
- Smith, J. (2022). Navigating patent landscapes in Eurasia. Journal of Patent Strategy, 15(4), 45-58.
- Eurasian Patent Database. (2023). Patent EA201100565 details.
